Zacks Small Cap Issues Pessimistic Estimate for PLX Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Stock analysts at Zacks Small Cap reduced their FY2025 earnings per share estimates for shares of Protalix BioTherapeutics in a report issued on Tuesday, March 18th. Zacks Small Cap analyst J. Vandermosten now anticipates that the company will post earnings of $0.43 per share for the year, down from their previous estimate of $0.44. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share.

Several other research firms also recently commented on PLX. StockNews.com downgraded Protalix BioTherapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday. HC Wainwright upped their price objective on Protalix BioTherapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, February 3rd.

Protalix BioTherapeutics Stock Performance

Protalix BioTherapeutics stock opened at $2.25 on Thursday. The stock has a 50-day simple moving average of $2.39 and a 200-day simple moving average of $1.74. The company has a market capitalization of $165.68 million, a P/E ratio of -17.31 and a beta of 0.72. Protalix BioTherapeutics has a fifty-two week low of $0.82 and a fifty-two week high of $2.76.

Hedge Funds Weigh In On Protalix BioTherapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sanctuary Advisors LLC acquired a new position in Protalix BioTherapeutics during the 3rd quarter worth approximately $38,000. Y Intercept Hong Kong Ltd purchased a new stake in Protalix BioTherapeutics in the 4th quarter valued at approximately $35,000. GSA Capital Partners LLP lifted its stake in Protalix BioTherapeutics by 8.5% in the 3rd quarter. GSA Capital Partners LLP now owns 435,213 shares of the company’s stock valued at $444,000 after buying an additional 33,969 shares in the last quarter. PFG Investments LLC purchased a new stake in Protalix BioTherapeutics in the 4th quarter valued at approximately $39,000. Finally, Virtu Financial LLC purchased a new stake in Protalix BioTherapeutics in the 3rd quarter valued at approximately $44,000. Institutional investors and hedge funds own 16.53% of the company’s stock.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.